EUVIMEDEUVIMED entdecken
Crossref

Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population.

European Journal of Clinical Pharmacy · 22.12.2025 · 7 (1) · 8083-8089

DOI: 10.61336/ejcp/25-08-495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacy, online erschienen am 22.12.2025.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) in children is a progressive condition associated with multiple complications, among which hypertension is one of the most frequent and clinically significant. Chronic hypertension increases cardiovascular morbidity and death and speeds up renal deterioration (1,2). Therefore, increasing renal outcomes and overall survival requires effective blood pressure control. Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACE inhibitors) are common pharmacological treatments; however, there is still little comparative data in pediatric populations.

Objective

To compare the efficacy of captopril and losartan in the management of hypertension among pediatric patients with chronic kidney disease. Methodology: This randomized controlled experiment was performed in the Department of Pediatrics at Khyber Teaching Hospital in Peshawar for a duration of six months. A total of 380 children aged 3 to 13 years with chronic kidney disease and hypertension were included. Patients were randomized into two cohorts: Group A got losartan (0.7 mg/kg once daily), while Group B received captopril (0.5 mg/kg twice daily). Baseline blood pressure was documented, and further readings were conducted after 6 weeks. Efficacy was characterized by a decrease in blood pressure of ≥10 mmHg. Data were examined using SPSS version 25, with p < 0.05 being statistically significant.

Results

The mean age of participants was 8.1 ± 2.9 years, with a slight male predominance (57.4%). After 6 weeks of treatment, efficacy was achieved in 68.4% of patients in the losartan group compared to 54.2% in the captopril group. The difference was statistically significant (p = 0.004). Losartan also demonstrated a greater mean reduction in blood pressure.

Conclusion

Losartan demonstrates superior efficacy compared to captopril in managing hypertension in juvenile patients with chronic kidney disease and may be regarded as a preferable treatment choice.

Zitieren

APA

(2025). Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population. European Journal of Clinical Pharmacy, 7(1), 8083-8089. https://doi.org/10.61336/ejcp/25-08-495

Vancouver

Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population. European Journal of Clinical Pharmacy. 2025;7(1):8083-8089. doi:10.61336/ejcp/25-08-495

BibTeX
@article{euvimed2025,
  title = {Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population},
  journal = {European Journal of Clinical Pharmacy},
  year = {2025},
  volume = {7},
  number = {1},
  pages = {8083--8089},
  doi = {10.61336/ejcp/25-08-495}
}
Kostenlos starten →